Analyst Price Target is GBX 137.50
▲ +21.25% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Alliance Pharma in the last 3 months. The average price target is GBX 137.50, with a high forecast of GBX 0 and a low forecast of GBX 0. The average price target represents a 21.25% upside from the last price of GBX 113.40.
Current Consensus is
The current consensus among 2 contributing investment analysts is to buy stock in Alliance Pharma.
Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. It holds the marketing rights of approximately 80 consumer healthcare and prescription medicine products. The company also offers medical devices, food supplements, and cosmetics. Alliance Pharma plc provides its products under the Aloclair, Anbesol, Asthon and Parsons, Atopiclair, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names. The company was founded in 1996 and is headquartered in Chippenham, the United Kingdom.